Neovasculgen® – has its effectiveness been proven? (Audiatur et altera pars)
AbstractThis work is controversial. It addresses only one question: is there a convincing evidence base at this stage of development on the positive effect of the already registered drug Neovasculgen® on the course of chronic lower limb ischemia in atherosclerotic lesions of the main vessels.
Conclusion. At the present stage, the evidence base on the benefits of using Neovasculgen® is insufficient to include this drug as a recommended therapeutic agent in the National Clinical Guidelines.
Keywords: chronic lower limb ischemia; angiogenesis; evidence base; stages of clinical trials
Funding. The study had no financial support.
Conflict of interest. The authors declare no conflicts of interest.
Authors’ contribution. Study conception and design – Vachev A.N., Bazylev V.V., Troitskiy A.V., Karpenko A.A.; data collection and handling – Vachev A.N., Bazylev V.V., Troitskiy A.V., Karpenko A.A.; draft manuscript preparation – Vachev A.N.; manuscript revision – Vachev A.N., Bazylev V.V., Troitskiy A.V., Karpenko A.A.
For citation: Vachev A.N., Bazylev V.V., Troitskiy A.V., Karpenko A.A. Neovasculgen® – has its effectiveness been proven? (Audiatur et altera pars). Angiology and Vascular Surgery. Journal named after Academician A.V. Pokrovsky. 2025; 31 (3): 16–9. DOI: https://doi.org/10.33029/1027-6661-2025-31-3-16-19
Dear readers!
Full-text version of the article is available only in paper version.